The biggest unanswered question in biomarker development for cancer is how to determine which patients will respond to targeted therapy or immunotherapy. Investigators around the world are trying to answer this through clinical trials and data mining, in addition to finding new tools to add to the mix.
Findings of a recent study suggest surgical choices in women with breast cancer may have long-term impacts on their quality of life. Investigators found that younger patients with breast cancer who underwent lumpectomy had better QOL outcomes than patients who had a mastectomy.
The United States Food and Drug Administration approved several maintenance therapies over the last few years for the management of platinum-sensitive recurrent ovarian cancer. Bevacizumab (Avastin), TKIs, or PARP inhibitors were among the treatments used in the clinical trials leading to these approvals.